Endo Pharmaceuticals Holdings and Penwest Pharmaceuticals filed a patent-infringement suit against Impax Laboratories over its application to make a generic version of the companies' painkiller, Opana ER. The dispute centers on an amendment of Impax's application to include 7.5 mg, 15 mg and 30 mg dosages of the drug.

Related Summaries